MyoKardia Stock Company Profile

Description

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops DCM-1, a drug compound that treats heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.